The level of PD-L1 expression can guide oncologists in selecting appropriate treatment regimens. For instance, patients with high PD-L1 expression may benefit more from immune checkpoint inhibitors compared to those with low or no expression. This stratification helps in optimizing therapeutic efficacy and minimizing unnecessary side effects.
